Lavoisier S.A.S.
14 rue de Provigny
94236 Cachan cedex
FRANCE

Heures d'ouverture 08h30-12h30/13h30-17h30
Tél.: +33 (0)1 47 40 67 00
Fax: +33 (0)1 47 40 67 02


Url canonique : www.lavoisier.fr/livre/medecine/management-of-castration-resistant-prostate-cancer/saad/descriptif_3177101
Url courte ou permalien : www.lavoisier.fr/livre/notice.asp?ouvrage=3177101

Management of Castration Resistant Prostate Cancer Current Clinical Urology Series

Langue : Anglais

Auteur :

This volume provides new data about the molecular biology of CRPC and a review of the definition, staging and prognostic factors that define CRPC. The book features an in depth review of proven therapeutic options, including bone targeted therapies, immunotherapy, chemotherapy and hormonal based therapies. Combination therapy as well as novel targeted approaches presently under investigations are also reviewed. The text provides up to date guidelines and algorithms for the management of CRPC based on international guidelines presently available as well as evidence based medicine. As a concise yet comprehensive summary of the current status of the field, Management of Castration Resistant Prostate Cancer serves as a very useful resource for physicians and researchers dealing with this challenging malignancy.

Part I. Castrate-Resistant Prostate Cancer: Clinical and Biological Considerations

Chapter 1 - Introduction - Castration Resistant Prostate Cancer: A Rapidly Expanding Clinical State and a Model for New Therapeutic Opportunities

Chapter 2. Evolution of Clinical States and the Castration Resistant Clinical Paradigm

Chapter 3. Molecular Mechanisms of Prostate Cancer Progression after Castration

Chapter 4. New Imaging Modalities

Part II. TREATMENT - The Androgen Receptor Signaling Axis biology and Therapeutic Opportunities, Systemic Chemotherapy, Immunotherapy, Bone Targeted Approaches and Radiopharmaceuticals

Chapter 5. Androgen Receptor Biology in Castration Resistant Prostate Cancer

Chapter 6. The Androgen Receptor as a Therapeutic Target for Castration-Resistant Prostate Cancer

Chapter 7. Approaches Targeting Androgen Synthesis (CYP 17 inhibitors)

Chapter 8. Cytotoxic Chemotherapy (Taxanes and Taxane Combinations)

Chapter 9. The Emerging Role of Immunotherapy in Castrate Resistant Prostate Cancer

Chapter 10. Bone Targeted Therapy: Rationale and Current Status

Chapter 11. Radium-223 and Other Radiopharmaceuticals in Prostate Cancer

Part III. New Drug Development: Clinical Trials Design in CRPC

Chapter 12. Introduction

Chapter 13. Phase I/II targeted treatments

Chapter 14. Defining Clinical Endpoints in Castration-resistant Prostate Cancer

Part IV. New Drug Development: Specific Targets

Chapter 15. Angiogenesis Inhibition in Castration Resistant Prostate Cancer

Chapter 16. Co-targeting Adaptive Survival Pathways

Chapter 17. Targeting the PI3K/AKT/mTOR Pathway in Prostate Cancer

Chapter 18. PARP Inhibitors

Chapter 19. Targeting C-Met/VEGF in Castration Resistant Prostate Cancer

Chapter 20. Epigenetics in Castration Resistant Prostate Cancer

Chapter 21. Undifferentiated Prostate Cancer and the Neuroendocrine Phenotype

Part V. Clinical Management Aspects

Chapter 22. Strategies Addressing Quality of Life: Patient Reported Outcome and Symptoms Management

Chapter 23. Evidence-Based Therapeutic Approaches for mCRPC patients: Rational Sequence of Standard Treatment Options and Design for Future Drug Development

All chapters are written by experts in their fields

Provides up to date guidelines and algorithms for management

Provides a concise yet comprehensive summary of the current status of the field

Date de parution :

Disponible chez l'éditeur (délai d'approvisionnement : 15 jours).

Prix indicatif 137,14 €

Ajouter au panier

Thèmes de Management of Castration Resistant Prostate Cancer :